Advertisement
ISRG vs SYK
Which Stock Would AI Choose? Intuitive Surgical (ISRG) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- ISRG reported Q1 2026 revenue growth of 23% year-over-year, beating estimates and driving positive sentiment in recent market activity.
- SYK faces headwinds from a recent cyberattack, contributing to a roughly 10% decline over the past 30 days, though upcoming Q1 earnings are anticipated.
- ISRG trades at a higher P/E ratio (price-to-earnings, 57) compared to SYK (39), reflecting premium growth expectations in robotic surgery.
- Year-to-date, ISRG shows stronger performance at around 17% gains versus SYK's 6%, amid broader medtech sector volatility.
- Both stocks operate in medtech but diverge in focus: ISRG on robotics, SYK on orthopedics, influencing their risk profiles and catalysts.
Introduction
Intuitive Surgical (ISRG) and Stryker (SYK) represent leading players in the medical technology sector, with ISRG dominating robotic-assisted surgery and SYK excelling in orthopedic devices and implants. This comparison analyzes their recent performance, growth drivers, and market positioning amid evolving healthcare demands. Traders seeking momentum plays and long-term investors eyeing medtech stability will find value in understanding their relative strengths, especially as procedure volumes and innovation shape sector trends. With both stocks navigating macroeconomic pressures and company-specific events, key insights emerge on valuation, sentiment, and potential trade-offs.
ISRG Overview and Recent Performance
Intuitive Surgical develops the da Vinci Surgical System, enabling minimally invasive procedures across specialties like urology and gynecology. In recent weeks, ISRG shares have shown resilience, with a year-to-date gain of approximately 17% despite broader market fluctuations. The company's Q1 2026 results highlighted robust demand, posting $2.77 billion in revenue, up 23% year-over-year, and non-GAAP EPS of $2.50, surpassing expectations. Procedure growth and recurring revenue from instruments and services, comprising 86% of total revenue, bolstered sentiment. Trading near $471 with a market cap over $166 billion, ISRG benefits from expanding robotic adoption, though high valuation and competition temper gains in volatile sessions.
SYK Overview and Recent Performance
Stryker focuses on orthopedics, spine, and surgical equipment, with a portfolio including joint replacement systems and endoscopy tools. Recent market activity has pressured SYK, with shares down about 10% over the past 30 days amid a cyberattack disrupting operations. Year-to-date performance stands at around 6%, with the stock trading near $329 and a $126 billion market cap. Investors await Q1 2026 earnings, expected to show revenue of $6.3 billion and EPS near $3.00, reflecting modest growth. Resilient fundamentals, including strong free cash flow and dividend growth over 32 years, support positioning, but cybersecurity risks and orthopedic cyclicality have influenced recent sentiment.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top 25 performers from over 350 AI trading bots, each employing diverse strategies across stocks, ETFs, and crypto. These bots vary by timeframe—from 5-minute scalps to 60-minute swings—and analysis type, including technical patterns, fundamentals, and volatility filters (low to high). Signal Agents provide real-time alerts without risk controls, Virtual Agents add customizable balances and management, while Brokerage Agents execute via Tickeron's platform. This selection highlights bots best suited to current conditions, offering win rates and returns tailored to market phases. Traders can explore these tools to automate strategies matching their risk tolerance and enhance decision-making in dynamic environments like medtech volatility.
Head-to-Head Comparison
ISRG and SYK both thrive in medtech but differ in business models: ISRG's razor-blade approach yields high-margin recurring revenue from da Vinci consumables, while SYK emphasizes hardware sales and M&A (mergers and acquisitions) for orthopedic expansion. Growth drivers contrast too—ISRG leverages procedure volume surges, SYK benefits from aging demographics in joints. Recent momentum favors ISRG post-earnings beat versus SYK's cyber setback. Risks include ISRG's elevated P/E and beta (1.68, indicating higher volatility), and SYK's lower beta (0.93) but sector exposure to elective procedures. Market sentiment tilts toward ISRG's innovation edge amid robotics hype.
Tickeron AI Verdict
Tickeron's AI models currently favor ISRG with a slight edge, driven by consistent trend strength, superior Q1 growth, and positive procedure catalysts positioning it ahead in relative performance. SYK offers stability and upcoming earnings potential but trails on recent momentum amid operational challenges. This assessment reflects observable data patterns, suggesting higher probability of near-term outperformance for ISRG in the current environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ISRG is a Buy and SYK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ISRG’s FA Score shows that 0 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- ISRG’s FA Score: 0 green, 5 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ISRG’s TA Score shows that 4 TA indicator(s) are bullish while SYK’s TA Score has 5 bullish TA indicator(s).
- ISRG’s TA Score: 4 bullish, 4 bearish.
- SYK’s TA Score: 5 bullish, 3 bearish.
Price Growth
ISRG (@Pharmaceuticals: Other) experienced а -0.61% price change this week, while SYK (@Medical/Nursing Services) price change was +0.19% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.97%. For the same industry, the average monthly price growth was -0.88%, and the average quarterly price growth was -13.78%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.83%. For the same industry, the average monthly price growth was +0.22%, and the average quarterly price growth was -16.42%.
Reported Earning Dates
ISRG is expected to report earnings on Jul 16, 2026.
SYK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-2.97% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-1.83% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| ISRG | SYK | ISRG / SYK | |
| Capitalization | 149B | 117B | 127% |
| EBITDA | 3.95B | 6.31B | 63% |
| Gain YTD | -25.478 | -12.798 | 199% |
| P/E Ratio | 51.28 | 35.38 | 145% |
| Revenue | 10.6B | 25.1B | 42% |
| Total Cash | 4.52B | N/A | - |
| Total Debt | 87M | 15.9B | 1% |
ISRG | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 20 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 59 | 67 | |
SMR RATING 1..100 | 51 | 57 | |
PRICE GROWTH RATING 1..100 | 63 | 61 | |
P/E GROWTH RATING 1..100 | 86 | 82 | |
SEASONALITY SCORE 1..100 | 50 | 37 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYK's Valuation (10) in the Medical Specialties industry is significantly better than the same rating for ISRG (81). This means that SYK’s stock grew significantly faster than ISRG’s over the last 12 months.
ISRG's Profit vs Risk Rating (59) in the Medical Specialties industry is in the same range as SYK (67). This means that ISRG’s stock grew similarly to SYK’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is in the same range as SYK (57). This means that ISRG’s stock grew similarly to SYK’s over the last 12 months.
SYK's Price Growth Rating (61) in the Medical Specialties industry is in the same range as ISRG (63). This means that SYK’s stock grew similarly to ISRG’s over the last 12 months.
SYK's P/E Growth Rating (82) in the Medical Specialties industry is in the same range as ISRG (86). This means that SYK’s stock grew similarly to ISRG’s over the last 12 months.
| ISRG | SYK | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 57% | 3 days ago 54% |
| Stochastic ODDS (%) | 3 days ago 70% | 3 days ago 63% |
| Momentum ODDS (%) | 3 days ago 53% | 3 days ago 58% |
| MACD ODDS (%) | 3 days ago 74% | 3 days ago 62% |
| TrendWeek ODDS (%) | 3 days ago 62% | 3 days ago 53% |
| TrendMonth ODDS (%) | 3 days ago 68% | 3 days ago 47% |
| Advances ODDS (%) | 3 days ago 68% | 3 days ago 55% |
| Declines ODDS (%) | 6 days ago 59% | 6 days ago 53% |
| BollingerBands ODDS (%) | 3 days ago 66% | 3 days ago 64% |
| Aroon ODDS (%) | 3 days ago 62% | 3 days ago 46% |
Advertisement
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.